1.
McGrath J, Saha S, Chant D & Welham J. Schizophrenia: a concise overview of
incidence, prevalence, and mortality. Epidemiol. Rev. 30, 67–76 (2008).
2.
福島貴子, 針間博彦. 精神病性障害. 脳科学辞典 https://bsd.neuroinf.jp/wiki/精神
病性障害 (2014) doi:10.14931/bsd.4581.
3.
Ikebuchi E, Nakagome K, Ikezawa S, Miura S, Yamasaki S, et al. Social cognition of
schizophrenia: bridging gap between brain science and psychosocial intervention.
Seishin Shinkeigaku Zasshi 114, 489–507 (in Japanese) (2012).
4.
Ustün B & Kennedy C. What is ‘functional impairment’? Disentangling disability
from clinical significance. World Psychiatry 8, 82–5 (2009).
5.
Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, et al. Monitoring and
care of young people at incipient risk of psychosis. Schizophr. Bull. 22, 283–303
(1996).
6.
Perkins DO, Gu H, Boteva K & Lieberman JA. Relationship between duration of
untreated psychosis and outcome in first-episode schizophrenia: a critical review and
meta-analysis. Am. J. Psychiatry 162, 1785–804 (2005).
7.
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, et al. Association between
duration of untreated psychosis and outcome in cohorts of first-episode patients. Arch.
Gen. Psychiatry 62, 975–83 (2005).
8.
American Psychiatric Association (著), 高橋三郎, 大野裕, 染矢俊幸 (訳). DSMⅣ-TR 精神疾患の診断・統計マニュアル 新訂版. (医学書院, 2004).
89
9.
Endicott J, Spitzer RL, Fleiss JL & Cohen J. The Global Assessment Scale. A
procedure for measuring overall severity of psychiatric disturbance. Arch. Gen.
Psychiatry 33, 766–71 (1976).
10.
Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M & Miettunen J. Duration of
untreated psychosis as predictor of long-term outcome in schizophrenia: systematic
review and meta-analysis. Br. J. Psychiatry 205, 88–94 (2014).
11.
Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, et al. Beyond the critical
period: longitudinal study of 8-year outcome in first-episode non-affective psychosis.
Br. J. Psychiatry 194, 18–24 (2009).
12.
Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, et al. Psychosis
prediction: 12-month follow up of a high-risk (‘prodromal’) group. Schizophr. Res. 60,
21–32 (2003).
13.
Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, et al. Prodromal
assessment with the structured interview for prodromal syndromes and the scale of
prodromal symptoms: predictive validity, interrater reliability, and training to
reliability. Schizophr. Bull. 29, 703–15 (2003).
14.
Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, et al. Mapping the onset of
psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J.
Psychiatry 39, 964–71 (2005).
15.
Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, et al. Symptom
assessment in schizophrenic prodromal states. Psychiatr. Q. 70, 273–87 (1999).
90
16.
McGlashan TH, Walsh BC, Woods SW (著), 水野雅文 (監訳), 小林啓之 (訳). サ
イコーシス・リスクシンドローム―精神病の早期診断実践ハンドブック. (医学
書院, 2011).
17.
Ruhrmann S, Schultze-Lutter F & Klosterkötter J. Early detection and intervention in
the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36 Suppl 3, S162-7
(2003).
18.
Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, et al.
Heterogeneity of psychosis risk within individuals at clinical high risk: a metaanalytical stratification. JAMA Psychiatry 73, 113–20 (2016).
19.
Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, et al. Predicting
psychosis: meta-analysis of transition outcomes in individuals at high clinical risk.
Arch. Gen. Psychiatry 69, 220–9 (2012).
20.
Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, et al. Moving
beyond transition outcomes: meta-analysis of remission rates in individuals at high
clinical risk for psychosis. Psychiatry Res. 209, 266–72 (2013).
21.
Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, et al. At risk for
schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic
outcomes in individuals at high clinical risk. Schizophr. Bull. 39, 923–32 (2013).
22.
Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer EM & Ruhrmann S.
Predicting first-episode psychosis by basic symptom criteria. Clin. Neuropsychiatry J.
Treat. Eval. 4, 11–22 (2007).
91
23.
de Wit S, Schothorst PF, Oranje B, Ziermans TB, Durston S, et al. Adolescents at
ultra-high risk for psychosis: long-term outcome of individuals who recover from their
at-risk state. Eur. Neuropsychopharmacol. 24, 865–73 (2014).
24.
Beck K, Studerus E, Andreou C, Egloff L, Leanza L, et al. Clinical and functional
ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis. Eur.
Psychiatry 62, 30–7 (2019).
25.
Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, et al. Preliminary
findings for two new measures of social and role functioning in the prodromal phase of
schizophrenia. Schizophr. Bull. 33, 688–702 (2007).
26.
Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, et al. At
clinical high risk for psychosis: outcome for nonconverters. Am. J. Psychiatry 168,
800–5 (2011).
27.
Hall RCW. Global Assessment of Functioning. A modified scale. Psychosomatics 36,
267–75 (1995).
28.
de Wit S, Wierenga LM, Oranje B, Ziermans TB, Schothorst PF, et al. Brain
development in adolescents at ultra-high risk for psychosis: longitudinal changes
related to resilience. NeuroImage. Clin. 12, 542–9 (2016).
29.
Morosini PL, Magliano L, Brambilla L, Ugolini S & Pioli R. Development, reliability
and acceptability of a new version of the DSM-IV Social and Occupational
Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta
Psychiatr. Scand. 101, 323–9 (2000).
30.
Näätänen R, Gaillard AWK & Mäntysalo S. Early selective-attention effect on evoked
potential reinterpreted. Acta Psychol. (Amst). 42, 313–29 (1978).
92
31.
Sallinen M, Kaartinen J & Lyytinen H. Is the appearance of mismatch negativity
during stage 2 sleep related to the elicitation of K-complex? Electroencephalogr. Clin.
Neurophysiol. 91, 140–8 (1994).
32.
Hari R, Hämäläinen M, Ilmoniemi R, Kaukoranta E, Reinikainen K, et al. Responses
of the primary auditory cortex to pitch changes in a sequence of tone pips:
neuromagnetic recordings in man. Neurosci. Lett. 50, 127–32 (1984).
33.
Halgren E, Baudena P, Clarke JM, Heit G, Liégeois C, et al. Intracerebral potentials to
rare target and distractor auditory and visual stimuli. I. Superior temporal plane and
parietal lobe. Electroencephalogr. Clin. Neurophysiol. 94, 191–220 (1995).
34.
Alho K. Cerebral generators of mismatch negativity (MMN) and its magnetic
counterpart (MMNm) elicited by sound changes. Ear Hear. 16, 38–51 (1995).
35.
Giard MH, Perrin F, Pernier J & Bouchet P. Brain generators implicated in the
processing of auditory stimulus deviance: a topographic event-related potential study.
Psychophysiology 27, 627–40 (1990).
36.
Scherg M, Vajsar J & Picton TW. A source analysis of the late human auditory evoked
potentials. J. Cogn. Neurosci. 1, 336–55 (1989).
37.
Opitz B, Rinne T, Mecklinger A, von Cramon DY & Schröger E. Differential
contribution of frontal and temporal cortices to auditory change detection: fMRI and
ERP results. Neuroimage 15, 167–74 (2002).
38.
Liasis A, Towell A, Alho K & Boyd S. Intracranial identification of an electric frontalcortex response to auditory stimulus change: a case study. Brain Res. Cogn. Brain Res.
11, 227–33 (2001).
93
39.
Rosburg T, Trautner P, Dietl T, Korzyukov OA, Boutros NN, et al. Subdural
recordings of the mismatch negativity (MMN) in patients with focal epilepsy. Brain
128, 819–28 (2005).
40.
Rinne T, Alho K, Ilmoniemi RJ, Virtanen J & Näätänen R. Separate time behaviors of
the temporal and frontal mismatch negativity sources. Neuroimage 12, 14–9 (2000).
41.
Garrido MI, Kilner JM, Kiebel SJ, Stephan KE & Friston KJ. Dynamic causal
modelling of evoked potentials: a reproducibility study. Neuroimage 36, 571–80
(2007).
42.
Garrido MI, Friston KJ, Kiebel SJ, Stephan KE, Baldeweg T, et al. The functional
anatomy of the MMN: a DCM study of the roving paradigm. Neuroimage 42, 936–44
(2008).
43.
MacLean SE & Ward LM. Temporo-frontal phase synchronization supports
hierarchical network for mismatch negativity. Clin. Neurophysiol. 125, 1604–17
(2014).
44.
Tada M, Kirihara K, Mizutani S, Uka T, Kunii N, et al. Mismatch negativity (MMN)
as a tool for translational investigations into early psychosis: a review. Int. J.
Psychophysiol. 145, 5–14 (2019).
45.
Shelley AM, Ward PB, Catts S V., Michie PT, Andrews S, et al. Mismatch negativity:
an index of a preattentive processing deficit in schizophrenia. Biol. Psychiatry 30,
1059–62 (1991).
46.
Erickson MA, Ruffle A & Gold JM. A meta-analysis of mismatch negativity in
schizophrenia: from clinical risk to disease specificity and progression. Biol.
Psychiatry 79, 980–7 (2016).
94
47.
Umbricht D & Krljes S. Mismatch negativity in schizophrenia: a meta-analysis.
Schizophr. Res. 76, 1–23 (2005).
48.
Javitt DC & Zukin SR. Recent advances in the phencyclidine model of schizophrenia.
Am. J. Psychiatry 148, 1301–8 (1991).
49.
Domino EF & Luby ED. Phencyclidine/schizophrenia: one view toward the past, the
other to the future. Schizophr. Bull. 38, 914–9 (2012).
50.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, et al. Subanesthetic effects
of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic,
perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199–
214 (1994).
51.
Javitt DC, Steinschneider M, Schroeder CE & Arezzo JC. Role of cortical N-methylD-aspartate receptors in auditory sensory memory and mismatch negativity generation:
implications for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 93, 11962–7 (1996).
52.
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, et al. Ketamine-induced
deficits in auditory and visual context-dependent processing in healthy volunteers:
implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry
57, 1139–47 (2000).
53.
Rosburg T & Kreitschmann-Andermahr I. The effects of ketamine on the mismatch
negativity (MMN) in humans - A meta-analysis. Clin. Neurophysiol. 127, 1387–1394
(2016).
54.
Toyomaki A, Kusumi I, Matsuyama T, Kako Y, Ito K, et al. Tone duration mismatch
negativity deficits predict impairment of executive function in schizophrenia. Prog.
Neuropsychopharmacol. Biol. Psychiatry 32, 95–9 (2008).
95
55.
Miyanishi T, Sumiyoshi T, Higuchi Y, Seo T & Suzuki M. LORETA current source
density for duration mismatch negativity and neuropsychological assessment in early
schizophrenia. PLoS One 8, e61152 (2013).
56.
Koshiyama D, Kirihara K, Tada M, Nagai T, Fujioka M, et al. Association between
mismatch negativity and global functioning is specific to duration deviance in early
stages of psychosis. Schizophr. Res. 195, 378–84 (2018).
57.
Light GA & Braff DL. Stability of mismatch negativity deficits and their relationship
to functional impairments in chronic schizophrenia. Am. J. Psychiatry 162, 1741–3
(2005).
58.
Kawakubo Y & Kasai K. Support for an association between mismatch negativity and
social functioning in schizophrenia. Prog. Neuro-Psychopharmacology Biol.
Psychiatry 30, 1367–8 (2006).
59.
Kim M, Kim SN, Lee S, Byun MS, Shin KS, et al. Impaired mismatch negativity is
associated with current functional status rather than genetic vulnerability to
schizophrenia. Psychiatry Res. 222, 100–6 (2014).
60.
Rasser PE, Schall U, Todd J, Michie PT, Ward PB, et al. Gray matter deficits,
mismatch negativity, and outcomes in schizophrenia. Schizophr. Bull. 37, 131–40
(2011).
61.
Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, et al. Modeling
deficits from early auditory information processing to psychosocial functioning in
schizophrenia. JAMA psychiatry 74, 37–46 (2017).
62.
Haigh SM, Coffman BA & Salisbury DF. Mismatch negativity in first-episode
schizophrenia: a meta-analysis. Clin. EEG Neurosci. 48, 3–10 (2017).
96
63.
Nagai T, Tada M, Kirihara K, Yahata N, Hashimoto R, et al. Auditory mismatch
negativity and P3a in response to duration and frequency changes in the early stages of
psychosis. Schizophr. Res. 150, 547–54 (2013).
64.
Bodatsch M, Brockhaus-Dumke A, Klosterkötter J & Ruhrmann S. Forecasting
psychosis by event-related potentials-systematic review and specific meta-analysis.
Biol. Psychiatry 77, 951–8 (2015).
65.
Okano H, Miyawaki A & Kasai K. Brain/MINDS: brain-mapping project in Japan.
Philos. Trans. R. Soc. Lond. B. Biol. Sci. 370, 20140310 (2015).
66.
Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, et al. Improvement in
mismatch negativity generation during d-serine treatment in schizophrenia: correlation
with symptoms. Schizophr. Res. 191, 70–9 (2018).
67.
Kim M, Lee TH, Yoon YB, Lee TY & Kwon JS. Predicting remission in subjects at
clinical high risk for psychosis using mismatch negativity. Schizophr. Bull. 44, 575–83
(2018).
68.
Tang Y, Wang J, Zhang T, Xu L, Qian Z, et al. P300 as an index of transition to
psychosis and of remission: data from a clinical high risk for psychosis study and
review of literature. Schizophr. Res. 226, 74–83 (2020).
69.
Kim M, Lee TY, Lee S, Kim SN & Kwon JS. Auditory P300 as a predictor of shortterm prognosis in subjects at clinical high risk for psychosis. Schizophr. Res. 165, 138–
44 (2015).
70.
Bramon E, Rabe-Hesketh S, Sham P, Murray RM & Frangou S. Meta-analysis of the
P300 and P50 waveforms in schizophrenia. Schizophr. Res. 70, 315–29 (2004).
97
71.
Wada M, Kurose S, Miyazaki T, Nakajima S, Masuda F, et al. The P300 event-related
potential in bipolar disorder: a systematic review and meta-analysis. J. Affect. Disord.
256, 234–49 (2019).
72.
Cui T, Wang PP, Liu S & Zhang X. P300 amplitude and latency in autism spectrum
disorder: a meta-analysis. Eur. Child Adolesc. Psychiatry 26, 177–90 (2017).
73.
Cropley VL, Lin A, Nelson B, Reniers RLEP, Yung AR, et al. Baseline grey matter
volume of non-transitioned ‘ultra high risk’ for psychosis individuals with and without
attenuated psychotic symptoms at long-term follow-up. Schizophr. Res. 173, 152–8
(2016).
74.
Chung Y, Allswede D, Addington J, Bearden CE, Cadenhead K, et al. Cortical
abnormalities in youth at clinical high-risk for psychosis: findings from the NAPLS2
cohort. NeuroImage. Clin. 23, 101862 (2019).
75.
Koike S, Takano Y, Iwashiro N, Satomura Y, Suga M, et al. A multimodal approach to
investigate biomarkers for psychosis in a clinical setting: the integrative neuroimaging
studies in schizophrenia targeting for early intervention and prevention (IN-STEP)
project. Schizophr. Res. 143, 116–24 (2013).
76.
Nagai T, Kirihara K, Tada M, Koshiyama D, Koike S, et al. Reduced mismatch
negativity is associated with increased plasma level of glutamate in first-episode
psychosis. Sci. Rep. 7, 2258 (2017).
77.
Koshiyama D, Kirihara K, Tada M, Nagai T, Koike S, et al. Duration and frequency
mismatch negativity shows no progressive reduction in early stages of psychosis.
Schizophr. Res. 190, 32–8 (2017).
98
78.
Kobayashi H, Nozaki S & Mizuno M. Reliability of the structured interview for
prodromal syndromes Japanese version (SIPS-J). JPN Bull Soc Psychiat 15, 168-74 (in
Japanese) (2007).
79.
Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, et al. Reliability and validity of
Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry
Clin. Neurosci. 59, 517–26 (2005).
80.
Matsuoka K, Uno M, Kasai K, Koyama K & Kim Y. Estimation of premorbid IQ in
individuals with Alzheimer’s disease using Japanese ideographic script (Kanji)
compound words: Japanese version of National Adult Reading Test. Psychiatry Clin.
Neurosci. 60, 332–9 (2006).
81.
松岡恵子, 金吉晴. 知的機能の簡易評価 Japanese Adult Reading Test（JART）.
(新興医学出版社, 2006).
82.
Inada T & Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin.
Neurosci. 69, 440–7 (2015).
83.
Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, et al. The Brief Assessment
of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard
neurocognitive battery. Schizophr. Res. 68, 283–97 (2004).
84.
Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, et al. Brief assessment of
cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin.
Neurosci. 61, 602–9 (2007).
85.
兼田康宏, 住吉太幹, 中込和幸, 池澤聰, 大森哲郎, 他. 統合失調症認知機能簡
易評価尺度日本語版（BACS-J）標準化の試み. 精神医学 55, 167–75 (2013).
99
86.
Lee TY, Kim SN, Correll CU, Byun MS, Kim E, et al. Symptomatic and functional
remission of subjects at clinical high risk for psychosis: a 2-year naturalistic
observational study. Schizophr. Res. 156, 266–71 (2014).
87.
Delorme A & Makeig S. EEGLAB: an open source toolbox for analysis of single-trial
EEG dynamics including independent component analysis. J. Neurosci. Methods 134,
9–21 (2004).
88.
Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic
curves. Acta Paediatr. 96, 644–7 (2007).
89.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical
statistics. Bone Marrow Transplant. 48, 452–8 (2013).
90.
Jahshan C, Heaton RK, Golshan S & Cadenhead KS. Course of neurocognitive deficits
in the prodrome and first episode of schizophrenia. Neuropsychology 24, 109–20
(2010).
91.
Niendam TA, Bearden CE, Zinberg J, Johnson JK, O’Brien M, et al. The course of
neurocognition and social functioning in individuals at ultra high risk for psychosis.
Schizophr. Bull. 33, 772–81 (2007).
92.
Woodward ND, Purdon SE, Meltzer HY & Zald DH. A meta-analysis of
neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in
schizophrenia. Int. J. Neuropsychopharmacol. 8, 457–72 (2005).
93.
Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, et al. Cognitive functioning
in prodromal psychosis: a meta-analysis. Arch. Gen. Psychiatry 69, 562–71 (2012).
94.
Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, et al. Impact of
neurocognition on social and role functioning in individuals at clinical high risk for
psychosis. Am. J. Psychiatry 168, 806–13 (2011).
100
95.
Fusar-Poli P, Rocchetti M, Sardella A, Avila A, Brandizzi M, et al. Disorder, not just
state of risk: meta-analysis of functioning and quality of life in people at high risk of
psychosis. Br. J. Psychiatry 207, 198–206 (2015).
96.
Rutigliano G, Valmaggia L, Landi P, Frascarelli M, Cappucciati M, et al. Persistence
or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor
functional outcomes in patients at ultra high risk for psychosis. J. Affect. Disord. 203,
101–10 (2016).
97.
Sawada K, Kanehara A, Sakakibara E, Eguchi S, Tada M, et al. Identifying
neurocognitive markers for outcome prediction of global functioning in individuals
with first-episode and ultra-high-risk for psychosis. Psychiatry Clin. Neurosci. 71,
318–27 (2017).
98.
Carrión RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, et al. Prediction of
functional outcome in individuals at clinical high risk for psychosis. JAMA psychiatry
70, 1133–42 (2013).
99.
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, et al. Threeyear course of clinical symptomatology in young people at ultra high risk for transition
to psychosis. Acta Psychiatr. Scand. 123, 36–42 (2011).
100. Atkinson RJ, Fulham WR, Michie PT, Ward PB, Todd J, et al. Electrophysiological,
cognitive and clinical profiles of at-risk mental state: the longitudinal Minds in
Transition (MinT) study. PLoS One 12, e0171657 (2017).
101. Lavoie S, Jack BN, Griffiths O, Ando A, Amminger P, et al. Impaired mismatch
negativity to frequency deviants in individuals at ultra-high risk for psychosis, and
preliminary evidence for further impairment with transition to psychosis. Schizophr.
Res. 191, 95–100 (2018).
101
102. Carrión RE, Cornblatt BA, McLaughlin D, Chang J, Auther AM, et al. Contributions
of early cortical processing and reading ability to functional status in individuals at
clinical high risk for psychosis. Schizophr. Res. 164, 1–7 (2015).
103. Kim M, Cho KIK, Yoon YB, Lee TY & Kwon JS. Aberrant temporal behavior of
mismatch negativity generators in schizophrenia patients and subjects at clinical high
risk for psychosis. Clin. Neurophysiol. 128, 331–9 (2017).
104. Higuchi Y, Sumiyoshi T, Seo T, Miyanishi T, Kawasaki Y, et al. Mismatch negativity
and cognitive performance for the prediction of psychosis in subjects with at-risk
mental state. PLoS One 8, e54080 (2013).
105. Molholm S, Martinez A, Ritter W, Javitt DC & Foxe JJ. The neural circuitry of preattentive auditory change-detection: an fMRI study of pitch and duration mismatch
negativity generators. Cereb. Cortex 15, 545–51 (2005).
106. Lee M, Sehatpour P, Hoptman MJ, Lakatos P, Dias EC, et al. Neural mechanisms of
mismatch negativity dysfunction in schizophrenia. Mol. Psychiatry 22, 1585–93
(2017).
107. Phillips HN, Blenkmann A, Hughes LE, Bekinschtein TA & Rowe JB. Hierarchical
organization of frontotemporal networks for the prediction of stimuli across multiple
dimensions. J. Neurosci. 35, 9255–64 (2015).
108. Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, et al. Cortical substrates
and functional correlates of auditory deviance processing deficits in schizophrenia.
NeuroImage. Clin. 6, 424–37 (2014).
109. Patterson TL, Goldman S, McKibbin CL, Hughs T & Jeste D V. UCSD PerformanceBased Skills Assessment: development of a new measure of everyday functioning for
severely mentally ill adults. Schizophr. Bull. 27, 235–45 (2001).
102
110. MacLean SE, Blundon EG & Ward LM. Brain regional networks active during the
mismatch negativity vary with paradigm. Neuropsychologia 75, 242–51 (2015).
111. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RKR, et al.
EPA guidance on the early intervention in clinical high risk states of psychoses. Eur.
Psychiatry 30, 388–404 (2015).
112. Devoe DJ, Farris MS, Townes P & Addington J. Interventions and social functioning
in youth at risk of psychosis: a systematic review and meta-analysis. Early Interv.
Psychiatry 13, 169–80 (2019).
113. Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, et al. D-serine for
the treatment of negative symptoms in individuals at clinical high risk of
schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group
mechanistic proof-of-concept trial. The lancet. Psychiatry 2, 403–12 (2015).
114. Cho S-E, Na K-S, Cho S-J & Kang SG. Low d-serine levels in schizophrenia: a
systematic review and meta-analysis. Neurosci. Lett. 634, 42–51 (2016).
115. Kay SR, Fiszbein A & Opler LA. The positive and negative syndrome scale (PANSS)
for schizophrenia. Schizophr. Bull. 13, 261–76 (1987).
116. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, et al. Characterization of
neurophysiologic and neurocognitive biomarkers for use in genomic and clinical
outcome studies of schizophrenia. PLoS One 7, e39434 (2012).
117. Garrido MI, Kilner JM, Stephan KE & Friston KJ. The mismatch negativity: a review
of underlying mechanisms. Clin. Neurophysiol. 120, 453–63 (2009).
118. Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, et al.
Disentangling early sensory information processing deficits in schizophrenia. Clin.
Neurophysiol. 123, 1942–9 (2012).
103
119. Kasai K, Yamada H, Kamio S, Nakagome K, Iwanami A, et al. Do high or low doses
of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An
EEG and MEG study. Clin. Neurophysiol. 113, 141–50 (2002).
104
...
論文の公開元へ
